Vimizim
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$2.2M
Transactions
2,253
Doctors
818
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $228,450 | 94 | 11 |
| 2022 | $276,114 | 280 | 154 |
| 2021 | $312,196 | 233 | 110 |
| 2020 | $281,106 | 204 | 116 |
| 2019 | $155,736 | 299 | 198 |
| 2018 | $511,357 | 728 | 293 |
| 2017 | $427,602 | 415 | 185 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 387 | 59.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $266,965 | 119 | 12.2% |
| Education | $257,347 | 241 | 11.7% |
| Travel and Lodging | $154,309 | 198 | 7.0% |
| Grant | $96,000 | 12 | 4.4% |
| Food and Beverage | $63,468 | 1,285 | 2.9% |
| Charitable Contribution | $30,000 | 1 | 1.4% |
| Honoraria | $11,667 | 5 | 0.5% |
| Consulting Fee | $7,300 | 5 | 0.3% |
Payments by Type
Research
$1.3M
387 transactions
General
$887,057
1,866 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Morquio A Registry Study MARS) | BioMarin Pharmaceutical Inc. | $751,374 | 0 |
| Morquio A Registry Study (MARS) | BioMarin Pharmaceutical Inc. | $301,877 | 0 |
| Morquio A Registry Study MARS | BioMarin Pharmaceutical Inc. | $154,527 | 0 |
| MPS VI Clinical Surveillance Program CSP) | BioMarin Pharmaceutical Inc. | $24,226 | 0 |
| Gait Analysis in Patients with MPS IVA Treated with Enzyme Replacement Therapy Dr. Hata). | BioMarin Pharmaceutical Inc. | $19,993 | 0 |
| Gait Motion Analysis of Patients with MPS IVA | BioMarin Pharmaceutical Inc. | $19,993 | 0 |
| Pregnancy with Morquio syndrome - What are patients' perspectivie and has ERT changed them | BioMarin Pharmaceutical Inc. | $17,408 | 0 |
| PKU Demographics, Outcomes, and Safety Registry | BioMarin Pharmaceutical Inc. | $16,107 | 0 |
Top Doctors Receiving Payments for Vimizim
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $1.5M | 408 |
| , MD | Pediatric Gastroenterology | Oakland, CA | $126,399 | 113 |
| , M.D | Pediatric Orthopaedic Surgery | Uniondale, NY | $64,207 | 89 |
| , MD | Orthopaedic Surgery | Seattle, WA | $61,173 | 98 |
| , MD | Clinical Genetics (M.D.) | Chicago, IL | $52,381 | 55 |
| , M.D | Pulmonary Disease | New York, NY | $31,545 | 13 |
| , MD | Orthopaedic Surgery | Wilmington, DE | $23,584 | 14 |
| , M.D | Pediatrics | Minneapolis, MN | $23,581 | 6 |
| , MD | Clinical Genetics (M.D.) | West Hartford, CT | $20,457 | 29 |
| , MD | Neurological Surgery | Chicago, IL | $19,868 | 6 |
| , MD | Radiation Oncology | Oakland, CA | $17,616 | 27 |
| , M.D | Clinical Genetics (M.D.) | Philadelphia, PA | $16,007 | 8 |
| , MD | Pediatrics | Chapel Hill, NC | $13,660 | 29 |
| , MD | Clinical Genetics (M.D.) | Salt Lake City, UT | $13,267 | 5 |
| , MD | Pediatric Otolaryngology | Saint Louis, MO | $12,536 | 5 |
| Maria Escolar | Pediatrics | Chapel Hill, NC | $11,465 | 7 |
| , MD | Pediatric Hematology-Oncology | Minneapolis, MN | $10,649 | 6 |
| , MD | Clinical Genetics (M.D.) | Houston, TX | $9,124 | 12 |
| , MD, PHD | Medical Genetics, Ph.D. Medical Genetics | Pittsburgh, PA | $8,939 | 10 |
| , M.D | Neurology with Special Qualifications in Child Neurology | New York, NY | $8,670 | 6 |
| , M.D | Clinical Genetics (M.D.) | Omaha, NE | $8,349 | 18 |
| , MD | Anesthesiology | Piedmont, CA | $6,922 | 6 |
| , MD | Pediatric Orthopaedic Surgery | New Orleans, LA | $6,653 | 7 |
| , MD | Clinical Genetics (M.D.) | Houston, TX | $6,298 | 14 |
| , MD | Pediatrics | Torrance, CA | $5,567 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $2.2M
- Total Doctors 818
- Transactions 2,253
About Vimizim
Vimizim is a biological associated with $2.2M in payments to 818 healthcare providers, recorded across 2,253 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2023. In 2023, $228,450 was paid across 94 transactions to 11 doctors.
The most common payment nature for Vimizim is "Unspecified" ($1.3M, 59.5% of total).
Vimizim is associated with 8 research studies, including "Morquio A Registry Study MARS)" ($751,374).